Research & Development
Pathology & AI
Gene silencing and gene editing: Page 2
Nucleai, Sirona Dx partner on tumor biomarker discovery
The partnership combines Nucleai's artificial intelligence (AI) spatial analytics platform with Sirona Dx's multiplex assay development expertise to identify novel spatial signatures in high-plex assays that predict responses to therapy and inform treatment decisions.
July 13, 2022
Bruker launches long-COVID assessment test
The test, PhenoRiskPacs RuO, uses a multiplexed combination of biomarkers discovered at the Australian National Phenome Center at Murdoch University.
July 7, 2022
StataDx licenses eRapid multiplexed biosensor technology
The firm has gained exclusive worldwide rights to eRapid in the fields of neurological, cardiovascular, and renal diseases.
July 4, 2022
Quotient discloses underwritten public offering price
The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.
June 23, 2022
Quotient, Theradiag to partner on autoimmune disease testing
Under the terms of their agreement, Theradiag will supply autoimmune reagents and multiconstituent quality controls for the development of autoimmune microarrays that will be used on the Quotient MosaiQ platform.
June 7, 2022
Anitoa launches portable test for dengue virus
The multiplex test, part of the company's Maverick line of RT-PCR devices, detects several target genes in a sample which have been shown by researchers to be highly expressed in patients who later develop serious symptoms, the company said.
May 4, 2022
Agendia highlights presentations at ESMO Breast Cancer 2022
The first poster presentation concluded that the next-generation sequencing versions of MammaPrint and BluePrint are equivalent to a centralized microarray test, according to the vendor.
May 3, 2022
iCura given CRO status by Akoya Biosciences
iCura provides diagnostic testing and services for the pharmaceutical industry, academic research centers, and partner CROs and laboratories. The company has recently focused its services on multiplexing immunofluorescence (IF)/immunohistochemistry (IHC), circulating tumor cells, and genomic services.
April 17, 2022
Ultivue, Paige partner to advance AI products
Efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue's novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels, the companies said.
April 7, 2022
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
Lunaphore, MGH collaborate on IVD work for solid tumors
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
Wellcome Institute touts COVID sequencing data at SLAS 2022
As part of WSI's sequencing work, the institute is developing and scaling an automated pipeline to produce SARS-CoV-2 libraries to support multiplexed sequencing on the Illumina NovaSeq platform, according to the poster.
February 3, 2022
Page 2 of 5